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686Resolved Hepatitis B Virus Infection Is Not Associated
with Worse Outcome after Allogeneic Hematopoietic
Stem Cell Transplantation
Carlos A. Ramos,1 Rima M. Saliba,1 Leandro de Padua Silva,1 Ola Khorshid,1
Elizabeth J. Shpall,1 Sergio Giralt,1 Poliana A. Patah,2 Chitra M. Hosing,1 Uday R. Popat,1
Gabriela Rondon,1 Yago Nieto,1 Richard E. Champlin,1 Marcos de Lima1Serologic evidence of resolved hepatitis B virus (HBV) infection has been associated with reactivation of hep-
atitis after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the true impact of this finding
is unknown. We conducted a retrospective matched-control analysis of the outcomes of 76 patients with
positive HBV core antibody (HBcAb) and negative HBV surface antigen (HBsAg) at the time of allo-HSCT
for hematologic or solid malignancies. Control patients (matched controls), with negative serology for
HBV and other viral hepatitides, were matched by age, diagnosis, disease risk, intensity of conditioning
regimen, and donor type. In addition, the HBcAb-positive patients and all seronegative patients (all controls,
n5 1858) undergoing transplantation during the same period were compared to adjust for other confound-
ing effects. Patient characteristics and baseline hepatic function studies were similar in the HBcAb-positive
and matched control groups. The cumulative incidence of hepatitis B reactivation (defined as the emergence
of HBsAg in serum) was 11.6% at 3 years. There were no significant differences in overall survival, relapse,
nonrelapse mortality, and incidence of acute graft-versus-host disease between the HBcAb-positive and con-
trol groups. Our data suggest that seropositivity for HBcAb and seronegativity for HBsAg at the time of
transplantation does not seem to adversely affect outcome after allo-HSCT.
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Despite a significant decrease in incidence in recent
years [1], an estimated 4.9% of the US population has
been infected with the hepatitis B virus (HBV) [2].
When the infection occurs after the age of 5 years, ap-
proximately 95% of individuals are able to successfully
eradicate it [3], as evidenced by clearance of the hepatitis
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6/j.bbmt.2009.12.532B surface antibody (HBsAb) in the serum, with persis-
tence of hepatitis B core antibody (HBcAb). This sero-
logic combination, referred to as resolved hepatitis
B [4], is likely to be seen in the allogeneic hematopoietic
stem cell transplantation (allo-HSCT) setting.
Although HBV reactivation (causing hepatitis
flare) is known to occur in 15%-50% of chronic virus
carriers (ie, HBsAg-positive individuals) who undergo
allo-HSCTwithout HBV prophylaxis [5-9], the risk of
reactivation (ie, reemergence of HBsAg) in patients
with evidence of resolved HBV is less well defined,
with previous series suggesting rates of 6%-86%
[10-15]. Furthermore, whereas several cases of fatal
fulminant hepatic failure associated with HBV reacti-
vation in chronic HBV carriers have been described
in that setting [16,17], the impact of resolved HBV
infection on outcome after allo-HSCT is unclear.
Because there is a definite risk of hepatitis reactiva-
tion after transplantation, possibly triggering signifi-
cant liver injury, there is some concern that resolved
hepatitis Bmay be associatedwith increased nonrelapse
mortality (NRM) after allo-HSCT. To address this
question, we performed a retrospective analysis of the
Biol Blood Marrow Transplant 16:686-694, 2010 687Resolved HBV Infection and Outcomes after Allogeneic Transplantationoutcomes of patients whowere seropositive forHBcAb
but negative for HBsAg at the time of allo-HSCT.PATIENTS AND METHODS
Patient Selection
This retrospective study was approved by the Uni-
versity of Texas M. D. Anderson Cancer Center
(UTMDACC) Office of Protocol Research. A waiver
of informed consent was obtained given the study
characteristics. Between January 1998 and March
2007, 76 patients with resolved HBV infection (de-
fined by the presence of HBcAb and absence of HBsAg
in serum) underwent an allogeneic bone marrow (BM)
or peripheral blood stem cell (PBSC) transplantation
at the UTMDACC. During the same period, a total
of 1858 patients with identical underlying hematologic
or solid malignancies who were seronegative for viral
hepatitides B and C underwent a first allo-HSCT
from a seronegative donor. Information on patient
clinical characteristics, pretransplantation history,
transplantation details, and posttransplantation course
is stored in a departmental database and was reviewed
as appropriate during the analysis. Laboratory and
pathology test data were obtained from our institu-
tion’s electronic medical records.Matching Procedure
We performed a matched case-controlled analysis,
in which each HBcAb-positive patient was paired with
one control subject selected from among all seronega-
tive patients (defining a group of ‘‘matched controls’’).
Patients were matched on age, underlying disease, dis-
ease stage category (low or high risk), type of condi-
tioning regimen (myeloablative or reduced intensity),
and donor type (sibling or unrelated), so as to control
for confounding effects. High-risk disease was defined
at the time of allo-HSCT as not being in remission for
acute leukemia, not being in first chronic phase for
chronic myelogenous leukemia, or having chemore-
sistant disease for the other lymphoid disorders. Met-
astatic solid tumors were considered high risk. If more
than one potential match existed, matches were ranked
by similarity, so that a control patient with the same ex-
act disease stage, the same exact treatment regimen,
and/or the same stem cell product source (BM vs
PBSC), as well as the closest age, was selected. All of
these requirements ensured selection of the best avail-
able unique control for each case. A control patient
could not be matched more than once. If more than
one case was initially matched to the same control,
then the best matching pair was kept, and the remain-
ing cases were matched to their next-best potential
control. A computer algorithm developed inMicrosoft
Access version 2003 (Microsoft Corp, Redmond, WA)was used for the matching procedure, to avoid any hu-
man bias. This procedure has been validated in a previ-
ous study [18]. Three patients were dropped from the
comparison with matched controls because no appro-
priate matched control was available. In addition to the
matched analysis, to adjust for any other confounding
effects, we compared the outcomes of all HBcAb-pos-
itive patients with those of all other patients undergo-
ing allo-HSCT for the same underlying diagnoses in
our institution during the same period (referred to as
‘‘all controls’’).
Conditioning Regimens and Graft-versus-Host
Disease, Fungal Infection, and Viral Infection
Prophylaxis
The conditioning regimen was tailored to the
underlyingmalignancy, at the discretion of the treating
physician. Most patients were treated following a dis-
ease-specific clinical protocol or according to a stan-
dard clinical pathway when treatment was provided
off-protocol. Graft-versus-host disease (GVHD) pro-
phylaxis almost always comprisedminidosemethotrex-
ate and tacrolimus, with the latter tapered after
approximately 6 months on average. Antifungal pro-
phylaxis consisted of fluconazole or voriconazole as
per our standard operating procedures. Antiviral pro-
phylaxis was provided with acyclovir or valacyclovir.
Only 2 patients in the HBcAb-positive cohort received
HBV-specific prophylaxis with lamivudine (see later).
Definitions
Baseline laboratory values
Baseline laboratory values were defined as the most
recent values obtained in tests performedbetween7 and
14 days before the date of transplantation, to ensure
that any changes because of the conditioning regimen
were not included as baseline characteristics. In cases
whereHBVDNAserum levelwas obtained, itwasmea-
sured by an outside reference laboratory using nucleic
acid hybridization or branched DNA amplification.
Veno-occlusive disease or sinusoidal obstruction
syndrome
Veno-occlusive disease (VOD) was defined by the
occurrence within 21 days of transplantation of hyper-
bilirubinemia (total serum bilirubin .2 mg/dL) and 2
of the following: hepatomegaly, ascites, or sudden
weight gain ($5% of baseline body weight) [19],
with no other explanation for these signs and
symptoms apparent at the time of diagnosis [20].
Liver dysfunction score
We analyzed all available results from laboratory
tests related to liver function performed after trans-
plantation in theHBcAb-positive andmatched control
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(ALT), alkaline phosphatase (ALP), and total bilirubin
were recorded posttransplantation. The correspond-
ing Common Terminology Criteria for Adverse
Events (CTCAE, version 3.0) grades for these 3 pa-
rameters were added to yield a score ranging from
0 to 12, which we call the liver dysfunction score, sum-
marizing the degree of abnormalities in those parame-
ters during the first 30 days (early period), between 31
and 100 days (intermediate period), and after 100 days
(late period) posttransplantation.
Causes of death
The primary cause of death was determined by the
attending physician at the time of the patient’s death
and reviewed by at least another investigator, taking
into account the clinical course, laboratory data, and
autopsy results (available in approximately 10% of
patients).Statistical Methods
The primary endpoints studiedwere overall survival
(OS) and NRM, estimated using the Kaplan-Meier and
cumulative incidence methods [21], respectively. Death
attributed to disease recurrence or progression was
considered a competing risk in the estimation of
NRM. The incidence of disease progression, acute
GVHD (aGVHD), and HBV reactivation also were es-
timated using the cumulative incidencemethod, consid-
ering death before the occurrence of the corresponding
events as a competing risk. Baseline clinical characteris-
tics and posttransplantation liver function parameters
were comparedusing the t test,c2 test, orMann-Whitney
test, as appropriate. Cox proportional hazards regres-
sion analysis [22] was used to evaluate prognostic fac-
tors for OS and NRM, including HBcAb status, in
the total cohort of patients (n 5 1934). Other factors
evaluated included age, underlying diagnosis, disease
risk, type of preparative regimen, and donor type. Those
factors found to be significant at the 0.1 level on univar-
iate analysis were included in amultivariatemodel to ad-
just for potential confounding effects. Cox regression
analysis also was used to compare outcomes of HBcAb-
positive patients and their matched controls on univari-
ate analysis. Statistical significance was determined at
the 0.05 level. All statistical analyses were performed
using Stata 9.0 (StataCorp, College Station, TX).RESULTS
Baseline Clinical Characteristics
The clinical characteristics of the HBcAb-positive
patients and controls are summarized in Table 1. In
the HBcAb-positive group, the median patient age
was 49 years, and there was a slight predominance ofmales (58%). Approximately half of the patients
(52%) had amyeloidmalignancy. Among the lymphoid
disorders in this group, non-Hodgkin lymphoma was
the most prevalent diagnosis, representing 19% of pa-
tients. Two patients had solid tumors (breast and kid-
ney). Approximately half of the patients (37 of 73)
had high-risk disease. The majority of the patients
(62%) received a PB–derived graft, and the remainder
received BM. Approximately 75% of the patients had
a matched related donor, and the remainder received
a graft from an HLA-matched unrelated donor. Some
42% of the patients received a reduced-intensity condi-
tioning regimen, in most cases a combination of fludar-
abine andmelphalan.Myeloablative strategies included
regimens bothwith andwithout busulfan and total body
irradiation. When busulfan was included, the dose was
adjusted by pharmacokinetic analysis [23]. The clinical
characteristics of the HBcAb-positive patients and the
matched control patients were virtually identical.
In accordance with specific clinical protocols or to
our department’s standard operating procedures,
a patient would have been excluded from transplanta-
tion if he or she had manifest liver dysfunction at
the time of evaluation for allo-HSCT, given the
high treatment-related mortality in this setting.
Therefore, all HBcAb-positive patients who under-
went allo-HSCT had ALT levels less than 4 times
the upper limit of normal (ULN) at the time of trans-
plantation (Table 1). Only 2 patients had mildly ele-
vated bilirubin levels (1.3 and 1.5 mg/dL). Only 3
HBcAb-positive patients had mildly prolonged pro-
thrombin time (PT). There were no significant differ-
ences in any of these parameters compared with the
matched control patients. Approximately one-third
of the patients in both groups had hypoalbuminemia,
a finding more likely associated with their underlying
malignancies rather than with liver dysfunction.
None of the patients had any stigmata of chronic liver
disease or clinical evidence of portal hypertension.
Thus, the HBcAb-positive patients had normal or
only slightly abnormal liver function, with the degree
of abnormality comparable to that of the matched
control population.
Viral loads were obtained before allo-HSCT in 9
patients and were nondetectable in 7 of these patients.
The other 2 patients had low-level viremia and
received lamivudine prophylaxis, according to current
guidelines at the time of evaluation. Liver biopsy was
performed before allo-HSCT in 2 patients with an
unknown viral load; one of these biopsies was unre-
markable, but the other demonstrated liver involve-
ment by chronic lymphocytic leukemia.Patient Outcomes
Median follow-up time was 47 months (range,
2-74 months) for HBcAb-positive patients and 37
Table 1. Patient Characteristics
HBcAb-Positive Matched Controls P All Controls P
Total, n 73 73 1858
Sex, n (%) .90 .80
Male 42 (58) 43 (59) 1103 (59)
Female 31 (42) 30 (41) 755 (41)
Age, years, median (range) 49 (24-68) 49 (11-69) .90 47 (2-80) .50
Diagnosis, n (%) .90 .80
AML/MDS 26 (36) 26 (36) 687 (37)
CML/MPD 12 (16) 12 (16) 254 (14)
Non-Hodgkin lymphoma 14 (19) 14 (19) 391 (21)
Acute lymphoblastic leukemia 7 (10) 7 (10) 171 (9)
Chronic lymphcytic leukemia 8 (11) 8 (11) 145 (8)
Multiple myeloma 3 (4) 3 (4) 75 (4)
Hodgkin lymphoma 1 (1) 1 (1) 87 (5)
Breast cancer 1 (1) 1 (1) 24 (1)
Renal cancer 1 (1) 1 (1) 24 (1)
Risk category, n (%) .90 .50
High 37 (51) 37 (51) 1020 (55)
Low 36 (49) 36 (49) 838 (45)
Cell type, n (%) .90 .70
Bone marrow 28 (38) 28 (38) 775 (42)
Peripheral blood 45 (62) 45 (62) 1083 (58)
Donor type, n (%) .90 .20
Related
HLA identical 50 (68) 51 (70) 982 (54)
One antigen mismatched 2 (3) 3 (4) 86 (5)
Two or 3 antigen mismatched 3 (4) 1 (1) 43 (2)
Unrelated
HLA identical 17 (23) 16 (22) 690 (38)
One antigen mismatched 1 (1) 2 (3) 30 (2)
Two antigen mismatched 2 (0)
Conditioning regimen .50
Reduced intensity 31 (42) 31 (42) 858 (46)
High dose/total body irradiation 12 (16) 8 (11) 233 (13)
High dose/busulfan 21 (29) 26 (36) 614 (33)
High dose/other 9 (12) 8 (11) 153 (8)
Abnormal laboratory studies
ALT > ULN, n (%) 11 (15) 8 (16) .50 ND
Range, IU/dL 63-215 58-164
AST > ULN, n (%) 4 (5) 5 (7) .70 ND
Range, IU/dL 51-227 49-55
ALP > ULN 11 (15) 5 (7) .10 ND
Range, IU/dL 127-223 136-434
Total bilirubin > ULN 2 (3) 2 (3) .90 ND
Range, mg/dL 1.3-1.5 1.5-1.7
Albumin < lower limit of normal 21 (29) 26 (36) .40 ND
Range, mg/dL) 2.3-3.4 2.6-3.4
PT > ULN + 1 second 3 (4) 6 (8) .30 ND
Range, seconds 13.9-14.8 13.9-15.6
Median alive follow-up, months (range) 47 (2-74) 37 (2-94) 27 (1-108)
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; MPD, myeloproliferative disorder;
ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal; ND, not determined.
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NRM after allo-HSCT was similar in the 2 groups
(25% and 17% at 1 year, respectively), with a hazard
ratio (HR) of NRM at 1 year of 1.5 (95% confidence
interval [CI], 0.7-31.1; P5 .3) for the HBcAb-positive
group, despite an apparent separation of the NRM
curves after 2 years (Figure 1 and Table 2). One-year
OS after allo-HSCT also was comparable in the 2
groups (66% and 64%, respectively), with an HR of
death at 1 year of 0.9 (95% CI, 0.6-1.7; P 5 .99) for
theHBcAb-positive group (Figure 2 andTable 2).Me-
dian OS was 25 months in the HBcAb-positive group
and 39 months in the control group; as with NRM,
the survival curves seem to separate after 2 years.The NRM and OS differences were not statistically
significant, however. The rate of disease progression
was also comparable in the 2 groups (Figure 1 and
Table 2).
BecauseHBV infection andGVHD share amajor
target organ in terms of immunologic response, we
were concerned that previously active HBV infec-
tion might act as a trigger for worse GVHD of the
liver. We found no statistically significant difference
in the incidence of aGVHD between groups, how-
ever (Figure 3). The cumulative incidence of grade
II-IV aGVHD was 28% in the resolved hepatitis B
group and 30% in the matched control group (HR,
1.0; 95% CI, 0.5-1.7; P 5 .9). The cumulative
Months Post Transplantation
0.0
0.2
0.4
0.6
0.8
1.0
Non-relapse mortality
P 1yr = 0.3
HR 1.4 (0.7-2.8)
HBcAb pos
Matched controls
Cu
m
u
la
tiv
e
 In
ci
de
n
ce
0 20 40 60 80 0 20 40 60 80
Months Post Transplantation
0.0
0.2
0.4
0.6
0.8
1.0
Disease progression
P 1yr = 0.9
HR 0.9 (0.5-1.9)
HBcAb pos
Matched controls
Cu
m
u
la
tiv
e
 In
ci
de
n
ce
Figure 1. Cumulative incidence of NRM of HBcAb-positive patients and controls. Death because of primary disease is the competing event for NRM.
Seropositivity for HBcAb was not associated with a statistically significant increase in the cumulative incidence of NRM or disease progression.
690 Biol Blood Marrow Transplant 16:686-694, 2010C. A. Ramos et al.incidence of grade III-IV aGVHD in the 2 groups
was 11% and 7%, respectively (HR, 1.6; 95% CI,
0.5-4.8; P 5 .4).
Confirmatory Analysis
We performed a confirmatory analysis of our re-
sults by extending the comparison of the outcomes
after transplantation of all HBcAb-positive patients
(n 5 76) to those of all the seronegative patients who
had undergone transplantation during the same period
for identical underlying malignancies (n5 1858). This
comparison was done while adjusting for potential
confounding effects in multivariate analysis. Similar
to our observations in the comparison with the
matched controls, we found no statistically significant
difference in NRM, OS, or disease progression be-
tween the HBcAb-positive group and the entire sero-
negative group (Table 2). Likewise, the cumulative
incidence of aGVHD (grades II-IV and III-IV) was
comparable in the 2 groups.
Posttransplantation Liver Complications
Because of concerns about possible higher liver
toxicity in the HBcAb-positive group, we looked for
any evidence of a higher propensity for hepatic compli-
cations in this group. With that in mind, we examined
the incidence of VOD, the frequency of markedly pro-
longed PT (as a surrogate for liver synthetic failure),
and the degree of abnormalities in tests commonlyTable 2. Outcome Data for All Groups Analyzed
Matched Analysis, Matched Con
Outcome HBcAb-Positive (n 5 73), % % HR (95% CI)
NRM
3 months 12 5 2.1 (0.6-6.9)
1 year 25 17 1.5 (0.7-31.1)
OS
3 months 88 92 1.5 (0.5-4.4)
1 year 66 64 0.9 (0.6-1.7)
NRM indicates nonrelapse mortality; OS, overall survival. Multivariate analysis
tation (n 51934).used to document hepatic injury: serum transaminases,
alkaline phosphatase, and bilirubin levels (Table 3).
There were 3 documented cases of VOD in theHBcAb
group and 1 case in the matched control group. Only 3
HBcAb-positive patients and 2 control patients had
a PT .10 seconds above the ULN at any time after
transplantation.
To summarize the degree of abnormalities in other
liver function tests, we calculated a liver dysfunction
score, as described above. The early posttransplanta-
tion period score was comparable between groups,
but there was a statistically significant difference in
the later posttransplantation period scores (between
30 and 100 days and.100 days), suggesting worse he-
patic complications in the HBcAb-positive group after
the first month. Analysis of the primary causes of death
(Table 4) did not reveal an obvious excess of deaths
attributed to liver failure, however. Despite frequent
evidence of preterminal liver dysfunction, most of
the cases occurred in the setting of multiorgan failure,
associated with infection or disease progression. The
one case with liver failure as the main cause of death
was not associated with HBV reactivation.
Eight HBcAb-positive patients (10%) had evidence
of HBV reactivation, defined as emergence of HBsAg
and disappearance of HBsAb (reverse seroconversion),
translating into cumulative incidences of 2.8% at 1
year and 11.6% at 3 years. The median time to reacti-
vation was 17 months (range, 8 to 31 months), and
most of the patients had been off immunosuppressiontrols (n 5 73) Multivariate Analysis, All Controls (n 5 1858)
P % HR (95% CI) P
.2 10 1.2 (0.6-2.4) .6
.3 23 1.1 (0.7-1.7) .7
.4 87 1.0 (0.5-1.9) .9
.99 56 0.8 (0.5-1.2) .3
was performed for the entire cohort of patients undergoing transplan-
Figure 2. OS of HBcAb-positive patients and controls. Seropositive
patients had comparable survival.
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tion between worsening liver function tests and
discontinuation of immunosuppression. Two patients
with evidence of reactivation experienced resolution
of HBV infection, one spontaneously and the other af-
ter treatment with lamivudine. Two patients died be-
cause of progression of underlying malignancy. Four
patients were chronically HBsAg-positive with mini-
mal transaminase elevation at the time of last follow-
up; none of these patients developed fulminant liver
failure.
Liver biopsy specimens were obtained after allo-
HSCT in 21 HBcAb-positive patients, including 7 of
the 8 patients with reverse seroconversion. Five
patients underwent 2 biopsies at different time points
after allo-HSCT. The most frequent pathological di-
agnoses were chronic hepatic GVHD (11 of 26 biop-
sies) and drug toxicity (9/26). Other findings were
chronic HBV infection (4/26), VOD (3/26), and acute
hepatitis (2/26). One biopsy specimen showed no
pathological changes.
All donors were HBsAg-negative. For 9 of the
HBcAb-positive patients, the donors (all matched sib-
lings) were HBsAb-positive, that is, had acquired nat-
ural immunity to HBV infection. None of these
patients had any evidence of reverse seroconversion.0 20 40 60 80 100
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Figure 3. Cumulative incidence of acute GVHD in HBcAb-positive patients a
nificant difference in the incidence of acute GVHD in the 2 groups.In addition, none of the 2 patients who received
lamivudine prophylaxis because of a detectable viral
load before transplantation experiencedHBV reactiva-
tion. Loss of HBcAb with persistent negativity of
HBsAg was documented in 24 patients (32%) after
allo-HSCT.DISCUSSION
The prevalence of resolved hepatitis B in our pa-
tients during the study period was approximately
3.9%, a value close to the most current estimates of
the frequency of HBcAb positivity together with
HBsAg negativity in the general population [1,2].
Our data demonstrate that transplant recipients with
such serology at the time of allo-HSCT have similar
outcomes as seronegative recipients. We reach identi-
cal conclusions regardless of whether we compare the
HBcAb-positive group directly to a clinically matched
seronegative cohort or, after multivariate adjustment,
to the entire seronegative population who underwent
allo-HSCT at our center for identical underlying
diseases.
Although there was a suggestion of worse late he-
patic toxicity in the HBcAb-positive patients, possibly
reflecting a deleterious effect on drug tolerance caused
by low-degree hepatic dysfunction associated with pre-
vious HBV infection, this seems to have had no influ-
ence on survival. Even the apparent separation of OS
and NRM curves after 2 years (which could in part re-
sult from the fact that HBcAb patients were followed
longer on average and thus were at risk for NRM for
a longer period) is not statistically significant.
In addition, despite a cumulative incidence of reac-
tivation of 11.6% at 3 years, no cases of fulminant
hepatic failure because of HBV reactivation were ob-
served. HBV can potentially remain dormant or in
a low-replication state after resolution of acuteHBV in-
fection, as illustrated by the finding of HBV DNA in
liver biopsy specimens [24] aswell as in circulatingblood
from HBsAg-negative and HBcAb-positive individuals0 20 40 60 80 100
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nd matched controls. Death is the competing event. There was no sig-
Table 3. Evidence of Liver Dysfunction in HBcAb-Positive
Patients and Matched Controls
Parameter
HBcAb-Positive
(n 5 73)
Matched Controls
(n 5 73) P
VOD cases, n 3 1 .62
PT > ULN + 10 seconds, n 3 2 .99
Liver dysfunction score
0-30 days 2.8 2.5 .34
31-100 days 2.9 1.9 .008*
>100 days 4.0 2.8 .01*
VOD indicates veno-occlusive disease; ULN, upper limit of normal.
* Statistically significant
692 Biol Blood Marrow Transplant 16:686-694, 2010C. A. Ramos et al.[25,26], a situation commonly referred to as occult hep-
atitis B [27]. This is thought to provide the substrate for
HBV reactivation associated with immunosuppressive
chemotherapy in patients with resolved hepatitis
B [28]. Previous studies have shown that reactivation
can occur after allo-HSCT,butmany reports are of sin-
gle cases [29-34] or limited series [12,14,35-37]. Larger
studies have suggested reactivation rates on the order of
6%-21% after allo-HSCT [10,11,13,15], but have not
assessed whether evidence of resolved HBV infection
in recipients is associated with worse outcomes in this
setting. Studies from Asia have shown that the level of
HBV viremia at baseline defines the risk of fulminant
hepatitis B after transplantation in individuals with
chronic hepatitis B (HBsAg-positive) [38], but that
this risk can be offset with proper antiviral therapy
[39,40].However,most authors agree that antiviral pro-
phylaxis is not warranted for recipients with resolved
HBV infection (HBsAg-negative), with the only gener-
ally accepted exception being those with detectable cir-
culating HBV DNA [9,41-43]. Our results support
these recommendations, although we do not have suffi-
cient data to address the role of HBV prophylaxis in in-
dividuals with detectable circulating HBV DNA.
Currently in our center, we routinely obtain HBV
DNA serum levels in patients seropositive for HBcAb
but negative for HBsAg. If results are positive, the pa-
tient is placed on prophylaxis, and viral load is moni-Table 4. Causes of Death for HBcAb-Positive Patients and
Matched Controls
HBcAb-Positive
(n 5 73)
Matched Controls
(n 5 73)
Total deaths 45 36
Cause of death, n (%)
Recurrence/persistence 16 (36) 19 (53)
Acute GVHD 5 (11) 4 (11)
Chronic GVHD 12 (27) 7 (19)
Graft rejection or failure 1 (3)
Infection 4 (9) 1 (3)
Liver failure (not VOD) 1 (2)
Heart failure 1 (2)
Respiratory failure 1 (2)
Multiorgan failure 2 (6)
Secondary malignancy 1 (3)
Other/unknown 5 (11) 1 (3)
GVHD indicates graft-versus-host disease; VOD, veno-occlusive dis-
ease. Matching criteria are described in the text.tored periodically peritransplantation; if negative, the
patient is not given prophylaxis, and viral load is not
checked unless there is evidence of liver dysfunction
peritransplantation. Several methods are available for
monitoring levels of circulatingHBVDNA. Commer-
cially available assays include those based on nucleic
acid hybridization, branched DNA amplification, or
real-time polymerase chain reaction (PCR) for detec-
tion of the HBV genome. First-generation methods
were limited by lack of standardization, low sensitivity
of detection (105-106 copies/mL), and narrow dynamic
ranges [44,45]. More recent tests, especially those
based on real-time PCR technology, provide better de-
tection (down to\100 copies/mL) and wider dynamic
ranges, and thus may be better suited to identifying
low-level virus replication, as is the case in early reac-
tivation or during antiviral therapy [46].
The present study has several strengths compared
with previous ones.We analyzed a large cohort at a sin-
gle center with uniform standard operating procedures
and a large number of patients treated on clinical trials.
Moreover, our departmental database contains carefully
recorded data regarding patient characteristics and clin-
ical course, with elements that are consistently captured
across treatment protocols. Finally, we had a sufficient
number of accumulated cases of identical or comparable
treatment regimens and disease stages to allow us to se-
lect closely matched controls using an unbiased algo-
rithm that had been validated in a previous study [18].
Regardless, there are limitations to our data. First,
viral studies were not obtained prospectively in our co-
hort, and it is possible that a greater proportion of pa-
tients experienced reactivation of HBV. However,
liver function test abnormalities were always investi-
gated as appropriate, including determination of
HBV activity, and only 8 cases of reactivation were de-
tected. Therefore, if there were any other instances of
HBV reactivation, they were likely clinically insignifi-
cant. Second, viral loads before allo-HSCT were
known in only a minority of patients, so whether there
was increased risk of reactivation in patients with oc-
cult HBV infection (ie, positive viral loads despite
HBsAg negativity) at the time of allo-HSCT is un-
clear. Viral loads, when obtained, were negative in all
but 2 HBcAb-positive patients, suggesting that the
majority of patients had nondetectable circulating
HBV DNA. None of the patients with a documented
negative viral load at the time of allo-HSCT had evi-
dence of HBV reactivation. Third, it is conceivable
that a few of the patients with HBcAb seropositivity
were false-positives for resolved HBV infection, espe-
cially because HBsAb results were not available for all
patients. Nevertheless, even if some of those individ-
uals were HBsAb-seronegative, the most likely expla-
nation for their seropositivity for HBcAb remains
previous HBV infection [3]. Thus, we believe that
only a very small proportion of these patients (if any)
Biol Blood Marrow Transplant 16:686-694, 2010 693Resolved HBV Infection and Outcomes after Allogeneic Transplantationmay have been false-positives. Finally, the HBsAb sta-
tus was unknown inmost donors, precluding analysis of
the effect of HBV vaccination of the donor on the rate
of hepatitis B reactivation. Natural donor immunity to
HBV has been described as a protective factor against
reactivation [47,48], and indeed none of the HBcAb-
positive recipients of a transplant from an HBcAb-
positive and HBsAg-negative donor had evidence of
HBV reactivation. Nonetheless, other authors have de-
scribed protection from donor vaccination [49], an ef-
fect that cannot be ascertained from our data.
In conclusion, serologic evidence of resolved hep-
atitis B infection at the time of allo-HSCT does not
seem to adversely affect outcomes, despite being asso-
ciated with reactivation of HBV infection in at least
10%of patients after allo-SCT.Therefore, seropositiv-
ity for HBcAb in the absence of HBsAg should not be
a contraindication to allo-HSCT, an important point
to keep in mind when evaluating patients for this proce-
dure. Further studies are needed to determine whether
any subgroups of patients necessarily require HBV pro-
phylaxis before transplantation.Nonetheless, long-term
close monitoring of these patients after transplantation
and preemptive antiviral therapy is recommended,
especially to detect any late complications.ACKNOWLEDGMENTS
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